Booming Global Obesity Drug Market

Table of Contents

1. Analyst View

2. The Global Obesity Epidemic

• 2.1 Defining Obesity
• 2.2 Prevalence of Obesity
• 2.3 The Cost of Obesity
• 2.4 Obesity is Linked to Higher Rates of Chronic Conditions
• 2.5 Obese Spend Significantly Higher on Healthcare

3. Available Weight-loss Techniques & Products

• 3.1 Weight-loss Surgery
• 3.2 Liposuction
• 3.3 Weight-loss Foods & Drinks
• 3.4 Diet Centres
• 3.5 Weight-loss Drugs

4. Obesity Drugs Market

• 4.1 Market Opportunity Assessment
• 4.2 Key Weight-loss Drugs
  • 4.2.1 Alli
    • 4.2.1.1 Market Performance
    • 4.2.1.2 Critical Success & Risk Factors
  • 4.2.2 Xenical
    • 4.2.2.1 Market Performance
    • 4.2.2.2 Critical Success & Risk Factors
  • 4.2.3 Acomplia
    • 4.2.3.1 Market Performance
    • 4.2.3.2 Critical Success & Risk Factors
  • 4.2.4 Meridia
    • 4.2.4.1 Market Performance
    • 4.2.4.2 Critical Success & Risk Factors
• 4.3 Weight-loss Drugs under Clinical Trials

5. Obesity in Developed Markets - A Brief Profile

• 5.1 US
• 5.2 Japan
• 5.3 Germany
• 5.4 UK
• 5.5 France
• 5.6 Italy
• 5.7 Spain

6. Obesity in Emerging Markets - A Brief Profile

• 6.1 Russia
• 6.2 India
• 6.3 Brazil
• 6.4 China

7. Critical Success Factors

• 7.1 Expanding Waistlines
• 7.2 High Unmet Needs
• 7.3 Self-Consciousness & Fulfillment
• 7.4 Strong Pipeline

8. Critical Risk Factors

• 8.1 High Failure Rate
• 8.2 High Consumer Demand
• 8.3 Reimbursement Issues
• 8.4 Side Effects

9. Key Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Roche Holding Ltd
• 9.3 Sanofi-Aventis
• 9.4 GlaxoSmithKline plc
• 9.5 Pfizer Inc.

List of Figures:

• Figure 2-1: Global - Overweight & Obese Adults* (in Million), 2005, 2007 & 2012
• Figure 2-2: Global - Proportion of Normal, Overweight & Obese Adults in Global Population (%), 2005, 2007 & 2012
• Figure 2-3: Relation between Obesity & Increasing Chronic Conditions (%)
• Figure 2-4: Odd Ratios for Selected Physical Conditions Related to Obesity, Aging, Smoking & Drinking
• Figure 2-5: Relation between Obesity & Increasing Healthcare Cost (%)
• Figure 3-1: US - Bariatric Surgeries Preformed (in Number), 2003 & 2007
• Figure 4-1: Global - Obesity Drugs Market* (in Million US$), 2005-2007 & 2012F
• Figure 4-2: Global - Obesity Drugs Market by Weight-loss Drugs (%), 2007
• Figure 4-3: Global - Alli Revenues (in Million US$), 2007 & 2012F
• Figure 4-4: Global - Xenical Revenues (in Million CHF), 2005, 2007 & 2012F
• Figure 4-5: Global - Acomplia Revenues (in Million Euro), 2006-Q3 2008
• Figure 4-6: Global - Meridia Revenues (in Million US$), 2006, 2007 & 2012F
• Figure 5-1: US - Obesity Drugs Market (in Million US$) 2007 & 2012F
• Figure 5-2: US - Weight-loss Market (in Billion US$), 2006, 2007E & 2012F
• Figure 5-3: UK - Prescriptions Dispensed for Obesity Drugs (in Number), 1999 & 2006
• Figure 6-1: Russia - Obesity Drugs Market by Weight-loss Drugs (%), 2006
• Figure 6-2: Russia - Slimming Food Supplements Market by Product (%), 2006
• Figure 6-3: India - Obesity Drugs Market (in Million US$), 2005 & 2006
• Figure 7-1: Comparison of Safety & Efficacy of Obesity Management Approaches

List of Tables:

• Table 2-1: Classification of Normal, Overweight & Obese on the Basis of BMI
• Table 3-1: US - Liposuction Statistics (2007)
• Table 4-1: Alli - Success & Risk Factor Analysis
• Table 4-2: Xenical - Success & Risk Factor Analysis
• Table 4-3: Acomplia - Success & Risk Factor Analysis
• Table 4-4: Meridia - Success & Risk Factor Analysis
• Table 4-5: Obesity Drugs in Phase-III Clinical Trials
• Table 4-6: Obesity Drugs in Phase-II Clinical Trials
• Table 4-7: Obesity Drugs in Phase-I Clinical Trials
• Table 5-1: US - Overweight & Obesity Statistics (1990, 2000, 2006, 2007E & 2012F)
• Table 5-2: Japan - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
• Table 5-3: Germany - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
• Table 5-4: UK - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
• Table 5-5: France - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
• Table 5-6: Italy - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
• Table 5-7: Spain - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
• Table 6-1: Russia - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
• Table 6-2: India - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
• Table 6-3: Brazil - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
• Table 6-4: China - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F
• Table 8-1: Potential Side-effects from Commonly Used Obesity Drugs
• Table 9-1: Abbott Laboratories - Strengths & Weaknesses
• Table 9-2: Roche Holding Ltd - Strengths & Weaknesses
• Table 9-3: Sanofi-Aventis - Strengths & Weaknesses
• Table 9-4: GlaxoSmithKline plc - Strengths & Weaknesses
• Table 9-5: Pfizer Inc. - Strengths & Weaknesses